{"symbol":"SH600062","secucode":"600062.SH","items":[{"title":"生物制造驶入发展快车道 产业资本密集布局","summary":"近期生物制造赛道产业与资本动作密集。多家初创企业相继完成新一轮融资，华润双鹤、鲁抗医药等上市公司持续加大布局力度，产业落地节奏显著提速。业内人士认为，生物制造行业正处于从技术创新向产业应用加速转化的关键期。在技术突破、政策支持和资本涌入的多重驱动下，行业有望在未来5-10年实现规模化发展，成为全球制造业绿色转型的重要引擎。","source":null,"url":"http://finance.eastmoney.com/news/1354,202608083835609467.html","info_code":"NW202608083835609467","show_time_timestamp":1786146845000,"show_time":"2026-08-08 07:54:05","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202608083835609467.html","url":"http://finance.eastmoney.com/news/1354,202608083835609467.html","code":"202608083835609467","infoCode":"NW202608083835609467","recordId":null,"source":null,"title":"生物制造驶入发展快车道 产业资本密集布局","updateTime":0,"showDateTime":1786146845000,"publishDate":0,"sRatingName":null,"summary":"近期生物制造赛道产业与资本动作密集。多家初创企业相继完成新一轮融资，华润双鹤、鲁抗医药等上市公司持续加大布局力度，产业落地节奏显著提速。业内人士认为，生物制造行业正处于从技术创新向产业应用加速转化的关键期。在技术突破、政策支持和资本涌入的多重驱动下，行业有望在未来5-10年实现规模化发展，成为全球制造业绿色转型的重要引擎。"}},{"title":"博瑞医药披露减重产品Ⅰ期结果；百奥赛图预计净利润涨超392%","summary":"药械审批海思科：创新药HSK51155片获临床试验批准通知书海思科8月6日公告，公司近日收到国家药品监督管理局下发的《药物临床试验批准通知书》，2026年5月受理的HSK51155片临床试验申请符合药品注册的有关要求，同意本品开展临床试验。HSK51155是公司自主研发的口服小分子镇痛药物，拟用于偏头痛治疗。","source":null,"url":"http://finance.eastmoney.com/news/1354,202608073834497920.html","info_code":"NW202608073834497920","show_time_timestamp":1786063115000,"show_time":"2026-08-07 08:38:35","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202608073834497920.html","url":"http://finance.eastmoney.com/news/1354,202608073834497920.html","code":"202608073834497920","infoCode":"NW202608073834497920","recordId":null,"source":null,"title":"博瑞医药披露减重产品Ⅰ期结果；百奥赛图预计净利润涨超392%","updateTime":0,"showDateTime":1786063115000,"publishDate":0,"sRatingName":null,"summary":"药械审批海思科：创新药HSK51155片获临床试验批准通知书海思科8月6日公告，公司近日收到国家药品监督管理局下发的《药物临床试验批准通知书》，2026年5月受理的HSK51155片临床试验申请符合药品注册的有关要求，同意本品开展临床试验。HSK51155是公司自主研发的口服小分子镇痛药物，拟用于偏头痛治疗。"}},{"title":"华润双鹤：普瑞巴林缓释片完成Ⅲ期临床试验登记公示","summary":"中证智能财讯华润双鹤（600062）8月6日晚间公告，全资子公司华润双鹤利民药业（济南）有限公司的普瑞巴林缓释片完成Ⅲ期临床试验登记公示。此次试验为评价普瑞巴林缓释片治疗带状疱疹后神经痛的有效性和安全性的随机、双盲、安慰剂对照、多中心临床试验。","source":null,"url":"http://finance.eastmoney.com/news/1354,202608063834091298.html","info_code":"NW202608063834091298","show_time_timestamp":1786020969000,"show_time":"2026-08-06 20:56:09","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202608063834091298.html","url":"http://finance.eastmoney.com/news/1354,202608063834091298.html","code":"202608063834091298","infoCode":"NW202608063834091298","recordId":null,"source":null,"title":"华润双鹤：普瑞巴林缓释片完成Ⅲ期临床试验登记公示","updateTime":0,"showDateTime":1786020969000,"publishDate":0,"sRatingName":null,"summary":"中证智能财讯华润双鹤（600062）8月6日晚间公告，全资子公司华润双鹤利民药业（济南）有限公司的普瑞巴林缓释片完成Ⅲ期临床试验登记公示。此次试验为评价普瑞巴林缓释片治疗带状疱疹后神经痛的有效性和安全性的随机、双盲、安慰剂对照、多中心临床试验。"}},{"title":"华润双鹤(600062.SH)：全资子公司普瑞巴林缓释片完成III期临床试验","summary":"2026年8月6日，华润双鹤(600062.SH)公告称，全资子公司双鹤利民普瑞巴林缓释片完成III期临床试验登记公示。根据公告，试验结论证明该药对PHN受试者疼痛疗效确切、起效较快，长期用药疗效维持稳定，整体安全性良好，不良反应较已上市产品相似或更低。公告显示，普瑞巴林缓释片是一种GABA受体阻滞药，用于治疗带状疱疹后神经痛及糖尿病周围神经病变相关神经性疼痛。","source":null,"url":"http://finance.eastmoney.com/news/1354,202608063833940426.html","info_code":"NW202608063833940426","show_time_timestamp":1786007955000,"show_time":"2026-08-06 17:19:15","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202608063833940426.html","url":"http://finance.eastmoney.com/news/1354,202608063833940426.html","code":"202608063833940426","infoCode":"NW202608063833940426","recordId":null,"source":null,"title":"华润双鹤(600062.SH)：全资子公司普瑞巴林缓释片完成III期临床试验","updateTime":0,"showDateTime":1786007955000,"publishDate":0,"sRatingName":null,"summary":"2026年8月6日，华润双鹤(600062.SH)公告称，全资子公司双鹤利民普瑞巴林缓释片完成III期临床试验登记公示。根据公告，试验结论证明该药对PHN受试者疼痛疗效确切、起效较快，长期用药疗效维持稳定，整体安全性良好，不良反应较已上市产品相似或更低。公告显示，普瑞巴林缓释片是一种GABA受体阻滞药，用于治疗带状疱疹后神经痛及糖尿病周围神经病变相关神经性疼痛。"}},{"title":"华润双鹤：子公司普瑞巴林缓释片完成Ⅲ期临床试验登记公示","summary":"8月6日，华润双鹤（600062）发布公告，全资子公司华润双鹤利民药业（济南）有限公司普瑞巴林缓释片完成Ⅲ期临床试验登记公示。公告提到，普瑞巴林缓释片是一种γ-氨基丁酸（GABA）受体阻滞药，用于治疗带状疱疹后神经痛及与糖尿病周围神经病变相关的神经性疼痛。","source":null,"url":"http://finance.eastmoney.com/news/1354,202608063833936514.html","info_code":"NW202608063833936514","show_time_timestamp":1786007640000,"show_time":"2026-08-06 17:14:00","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202608063833936514.html","url":"http://finance.eastmoney.com/news/1354,202608063833936514.html","code":"202608063833936514","infoCode":"NW202608063833936514","recordId":null,"source":null,"title":"华润双鹤：子公司普瑞巴林缓释片完成Ⅲ期临床试验登记公示","updateTime":0,"showDateTime":1786007640000,"publishDate":0,"sRatingName":null,"summary":"8月6日，华润双鹤（600062）发布公告，全资子公司华润双鹤利民药业（济南）有限公司普瑞巴林缓释片完成Ⅲ期临床试验登记公示。公告提到，普瑞巴林缓释片是一种γ-氨基丁酸（GABA）受体阻滞药，用于治疗带状疱疹后神经痛及与糖尿病周围神经病变相关的神经性疼痛。"}}]}